[18F]FDG与[68Ga]Ga-FAPI-04 PET/CT显像对高级别神经内分泌肿瘤患者的结局预测
单中心回顾性分析纳入20例高级别神经内分泌肿瘤患者,比较[18F]FDG与[68Ga]Ga-FAPI-04 PET/CT的视觉评估与定量参数对无进展生存期(PFS)的预测价值。存在FDG阳性/FAPI阴性病灶者PFS显著缩短(4个月 vs 9个月,P=0.0063),两种示踪剂的肿瘤体积及[18F]FDG的TLU亦与PFS相关。
要点
- 45%(9/20)患者存在FDG+/FAPI-病灶,其PFS为4个月,无此类病灶者为9个月(P=0.0063)。
- 单因素分析示[18F]FDG与[68Ga]Ga-FAPI-04的肿瘤体积均与PFS相关,[18F]FDG的TLU亦相关。
- 双示踪剂PET/CT或有助于指导治疗决策或识别高危病灶以追加局部治疗。
核心结论
- 存在不一致的FDG+/FAPI-病灶与显著缩短的PFS相关,可能提示侵袭性更强、易早期进展的疾病。
- 对高度侵袭性神经内分泌肿瘤患者行双示踪剂PET/CT可能有助于指导治疗决策或识别高危病灶以追加局部治疗。
研究设计与样本
- 单中心回顾性分析,纳入20例高级别神经内分泌肿瘤患者,均行[18F]FDG与[68Ga]Ga-FAPI-04 PET/CT。
- 视觉比较两次PET显像并记录FDG阳性/FAPI阴性(FDG+/FAPI-)病灶。
- 以40%病灶阈值为基础,定量评估两种示踪剂的最大、峰值、平均SUV、肿瘤体积(TV)及总病灶摄取(TLU=TV×SUVmean)。
- 采用log-rank检验或单因素Cox回归分析定量与视觉分析结果与PFS的相关性。
- PFS以RECIST 1.1影像学、临床疾病进展征象或死亡定义。
主要发现
- 原发肿瘤多数位于胃肠道(13/20例,65%),5/20例(25%)为原发灶不明癌。
- 9/20例(45%)患者检出FDG+/FAPI-病灶。
- 有FDG+/FAPI-病灶者PFS为4个月,无FDG+/FAPI-转移灶者PFS为9个月(P=0.0063,log-rank检验;HR 5.637,95%CI 1.619-26.16,P=0.0110,单因素Cox回归)。
- 单因素分析示PFS与[18F]FDG的TV相关(平均TV 258±588 cm3;每10 cm3 HR 1.024,95%CI 1.007-1.046,P=0.0204),与[68Ga]Ga-FAPI-04的TV相关(平均TV 130±192 cm3;每10 cm3 HR 1.032,95%CI 1.001-1.062,P=0.0277),与[18F]FDG的TLU相关(平均TLU 1,931±4,248 cm3;每10 cm3 HR 1.004,95%CI 1.001-1.007,P=0.0135)。
关键数值与推荐
- 视觉分析以FDG+/FAPI-病灶存在与否分组,有该病灶者PFS 4个月 vs 无该病灶者PFS 9个月(P=0.0063)。
- 定量分析采用40%病灶阈值计算SUV、TV与TLU。
- PFS以RECIST 1.1影像学、临床进展征象或死亡定义。
临床怎么用
- 作者认为,FDG+/FAPI-病灶的存在与显著缩短的PFS相关,可能提示更具侵袭性、易早期进展的疾病。
- 作者认为,对高度侵袭性神经内分泌肿瘤患者行双示踪剂PET/CT可能有助于指导治疗决策或识别高危病灶以追加局部治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to quantitatively investigate the prognostic value of PET-based biomarkers on [18F]FDG and [68Ga]Ga-fibroblast activation protein inhibitor (FAPI)-04 PET/CT in patients with highly aggressive neuroendocrine neoplasms (NENs) and to compare the visually assessed differences in uptake on both examinations with progression-free survival (PFS). Methods: In this single-center retrospective analysis, 20 patients with high-grade NENs had undergone [18F]FDG and [68Ga]Ga-FAPI-04 PET. Both PET scans were visually compared, and the presence of [18F]FDG-positive, [68Ga]Ga-FAPI-04-negative (FDG+/FAPI-) lesions was noted. In addition, we assessed maximum, peak, and mean SUV; tumor volume (TV); and total lesion uptake (TLU = TV × SUVmean) for both radiotracers using a 40% lesion-based threshold. The results of quantitative and visual analysis were correlated with PFS using log-rank analysis or univariate Cox regression. PFS was defined radiographically using RECIST 1.1., clinically using signs of disease progression, or as death. Results: Most primary tumors were located in the gastrointestinal tract (13/20 patients, 65%) or were cancer of unknown primary (5/20 patients, 25%). FDG+/FAPI- lesions were found in 9 of 20 patients (45%). Patients with FDG+/FAPI- lesions had a significantly decreased PFS of 4 mo, compared with 9 mo for patients without FDG+/FAPI- metastases (P = 0.0063 [log-rank test]; hazard ratio [HR], 5.637; 95% CI 1.619-26.16; P = 0.0110 [univariate Cox regression]). On univariate analysis, a significant correlation was also found between PFS and TV for both radiotracers ([18F]FDG: mean TV, 258 ± 588 cm3; HR, 1.024 [per 10 cm3]; 95% CI, 1.007-1.046; P = 0.0204) ([68Ga]Ga-FAPI-04: mean TV, 130 ± 192 cm3; HR, 1.032 [per 10 cm3]; 95% CI, 1.001-1.062; P = 0.0277) and TLU on [18F]FDG PET (mean TLU, 1,931 ± 4,248 cm3; HR, 1.004 [per 10 cm3]; 95% CI, 1.001-1.007; P = 0.0135). Conclusion: The presence of discordant FDG+/FAPI- lesions is associated with a significantly shorter PFS, which might indicate more aggressive disease prone to early progression. Dual-tracer PET/CT of patients with highly aggressive NENs could help guide treatment decisions or identify high-risk lesions for additional local therapeutic approaches.
引用
- Michalski K, Kosmala A, Hartrampf PE, et al. [18F]FDG and [68Ga]Ga-FAPI-04 Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine Neoplasms. J Nucl Med. 2024. PMID: 39477500. doi:10.2967/jnumed.124.268288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。